I. Pašić

发表

Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation

J. Lipton, A. Viswabandya, J. Mattsson, 2020, Annals of Hematology.

Anti‐thymocyte Globulin and Post‐Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen‐A and ‐B mismatched donors

J. Lipton, A. Viswabandya, M. Remberger, 2021, European journal of haematology.

Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infections

J. Lipton, A. Viswabandya, E. Atenafu, 2021, Leukemia & lymphoma.

Experience Using Anti-Thymocyte Globulin With Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Peripheral Blood Haploidentical Stem Cell Transplantation.

J. Lipton, A. Viswabandya, E. Atenafu, 2021, Transplantation and cellular therapy.

Current approach to the treatment of chronic myeloid leukaemia.

J. Lipton, Ivan Pašić, I. Pašić, 2017, Leukemia research.

The Bloom syndrome helicase BLM interacts with TRF2 in ALT cells and promotes telomeric DNA synthesis.

M. Ikura, M. Meyn, D. Stavropoulos, 2002, Human molecular genetics.

IMPROVING SAFETY AND OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE-CENTRE EXPERIENCE.

J. Lipton, A. Viswabandya, M. Remberger, 2022, Transplantation and cellular therapy.

Tobacco, alcohol, drugs consumption, and perception about the family functioning among adolescents in Tuzla Canton

V. Ferković, Maida Mulić, Azra Kurtić, 2017 .

Multiplex proteomics using proximity extension assay for the identification of protein biomarkers predictive of acute graft-vs.-host disease in allogeneic hematopoietic cell transplantation

E. Diamandis, J. Lipton, I. Prassas, 2023, Clinical chemistry and laboratory medicine.

Recurrent focal copy-number changes and loss of heterozygosity implicate two noncoding RNAs and one tumor suppressor gene at chromosome 3q13.31 in osteosarcoma.

David Malkin, Ana Novokmet, Adam Shlien, 2010, Cancer research.

Outcomes of patients diagnosed with chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation: Results from a tertiary care center.

J. Lipton, A. Viswabandya, J. Mattsson, 2021, Hematology/oncology and stem cell therapy.

Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients

V. Kulasingam, Deepali Kumar, A. Humar, 2022, Transplantation and Cellular Therapy.

Clinical prevalence and outcome of cardiovascular events in the first 100 days postallogeneic hematopoietic stem cell transplant

J. Lipton, A. Viswabandya, E. Atenafu, 2020, European journal of haematology.

Comparison of the Prognostic Ability of the HCT-CI, the Modified EBMT, and the EBMT-ADT Pre-transplant Risk Scores for Acute Leukemia.

J. Lipton, A. Viswabandya, S. Cyriac, 2021, Clinical lymphoma, myeloma & leukemia.

Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia

M. Minden, Zhaolei Zhang, Steven M. Chan, 2021, Bone Marrow Transplantation.

Less is More: Superior GVHD-Free/Relapse-Free Survival with Reduced Intensity Conditioning and Dual T-cell Depletion in AML.

A. Viswabandya, J. Mattsson, F. Michelis, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic hematopoietic stem cell transplantation in patients with therapy‐related hematologic malignancies developing after multiple myeloma

J. Lipton, A. Viswabandya, J. Mattsson, 2022, European journal of haematology.

NBN gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer

Dorota H. Sendorek, T. H. van der Kwast, W. Lam, 2014, Oncotarget.

Pretransplant bone marrow cellularity and blood count recovery are not associated with relapse or survival risk following allogeneic stem cell transplant for AML in CR

J. Lipton, A. Viswabandya, J. Mattsson, 2021, European journal of haematology.

Pilot prospective study of Frailty and Functionality in routine clinical assessment in allogeneic hematopoietic cell transplantation

J. Lipton, A. Viswabandya, E. Atenafu, 2020, Bone Marrow Transplantation.

The oncogenic and growth-suppressive functions of the integrin-linked kinase are distinguished by JNK1 expression in human cancer cells

D. Malkin, G. Hannigan, Adam D. Durbin, 2010, Cell cycle.

Refined hepatic grading system in chronic graft‐versus‐host disease improves prognostic risk stratification of long‐term outcomes

J. Lipton, A. Viswabandya, J. Mattsson, 2021, European journal of haematology.

Clonal hematopoiesis in the donor does not adversely affect long-term outcomes following allogeneic hematopoietic stem cell transplantation: result from a 13-year follow-up

T. Biezuner, Zhaolei Zhang, J. Lipton, 2023, Haematologica.

Moderate-severe grade of chronic graft versus host disease and younger age (less than 45 years old) are risk factors for avascular necrosis in adult patients undergoing allogeneic hematopoietic cell transplantation

J. Lipton, A. Viswabandya, S. Bhella, 2015, Annals of Hematology.

Interaction between High-Dose Intravenous Busulfan and Post-Transplant Cyclophosphamide on Hemorrhagic Cystitis after Allogeneic Hematopoietic Cell Transplantation.

J. Lipton, A. Viswabandya, T. Mazzulli, 2023, Transplantation and cellular therapy.

Risk factors for graft failure in allogeneic hematopoietic stem cell transplantation: a single-center study

A. Viswabandya, M. Remberger, J. Lipton, 2020, Cellular Therapy and Transplantation.

Outcomes of adult patients with acute myeloid leukemia and unsuccessful cytogenetic analysis undergoing allogeneic hematopoietic stem cell transplantation.

J. Lipton, A. Viswabandya, J. Mattsson, 2020, Hematology/oncology and stem cell therapy.

Subcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients: A prospective study of feasibility, safety, and healthcare resource use.

G. Dranitsaris, J. Lipton, A. Viswabandya, 2021, Hematology/oncology and stem cell therapy.

Prolactin, a potential biomarker for chronic GVHD activity

S. Ezzat, J. Lipton, A. Viswabandya, 2020, European journal of haematology.

Bloodstream Infections and Outcomes Following Allogeneic Hematopoietic Cell Transplantation: a Single-Center Study.

J. Lipton, A. Viswabandya, M. Remberger, 2021, Transplantation and cellular therapy.

Impact of age on hospitalization and outcomes post allogeneic hematopoietic cell transplantation outcome, a single center experience

J. Lipton, A. Viswabandya, I. Novitzky-Basso, 2023, Annals of Hematology.

Two BRM promoter polymorphisms predict poor survival in patients with hepatocellular carcinoma

Geoffrey Liu, R. Hung, Wei Xu, 2018, Molecular carcinogenesis.

Inferior outcomes with reduced intensity conditioning followed by allogeneic hematopoietic cell transplantation in fit individuals with acute lymphoblastic leukemia: a Canadian single-center study and a comparison to registry data

J. Lipton, K. Schultz, Rajat Kumar, 2021, Leukemia & lymphoma.

Comparison of outcomes after second allogeneic hematopoietic cell transplantation versus donor lymphocyte infusion in allogeneic hematopoietic cell transplant patients

J. Lipton, A. Viswabandya, J. Mattsson, 2021, Clinical Lymphoma Myeloma and Leukemia.

Ikirara Insertions Reveal Five New Anopheles gambiae Transposable Elements in Islands of Repetitious Sequence

Anne Tran, P. Romans, N. Quercia, 2001, Journal of Molecular Evolution.

Impact of hematopoietic cell transplant frailty scale on transplant outcome in adults

J. Lipton, A. Viswabandya, S. Alibhai, 2022, Bone Marrow Transplantation.

Chronic kidney disease, survival and graft-versus-host-disease-free/relapse-free survival in recipients of allogeneic hematopoietic stem cell transplant

J. Mattsson, A. Kitchlu, Shiyi Chen, 2022, Clinical Kidney Journal.

Incidence, Outcomes and Predictors of Acute Kidney Injury Post Allogeneic Stem Cell Transplant

J. Mattsson, A. Kitchlu, Shiyi Chen, 2020 .

ATG-Ptcy-CSA for Gvhd Prevention in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation for Adults with Hematological Malignancies

J. Lipton, A. Viswabandya, E. Atenafu, 2022, Blood.

Ptcy-ATG-CSA Vs. ATG-MMF-CSA for Gvhd Prevention for 10/10 HLA Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

J. Lipton, A. Viswabandya, E. Atenafu, 2022, Blood.

Influence of FLT3‐ITD and NPM1 status on allogeneic hematopoietic cell transplant outcomes in patients with cytogenetically normal AML

J. Lipton, A. Viswabandya, H. Messner, 2019, European journal of haematology.

The 17‐gene stemness score associates with relapse risk and long‐term outcomes following allogeneic haematopoietic cell transplantation in acute myeloid leukaemia

M. Minden, Steven M. Chan, Tong Zhang, 2022, EJHaem.

Prognostic implication of pre-transplant FEV1 on long-term outcomes following allogeneic hematopoietic stem cell transplantation.

J. Lipton, A. Viswabandya, T. Marras, 2023, European journal of haematology.

Acute kidney injury within 100 days post allogeneic hematopoietic cell transplantation is associated with increased risk of post-transplant complications and poor transplant outcomes

J. Mattsson, A. Kitchlu, Shiyi Chen, 2022, Bone Marrow Transplantation.

Propensity score matching analysis comparing the efficacy and steroid tapering benefit of extracorporeal photopheresis to best available therapy in third-line or beyond treatment for chronic GvHD.

A. Viswabandya, Christopher J. Patriquin, I. Novitzky-Basso, 2023, Transplantation and cellular therapy.

Single centre retrospective analysis of extracorporeal photopheresis (ECP) therapy in patients heavily pre-treated for chronic graft-versus-host disease (cGvHD) with steroid failure.

A. Viswabandya, Christopher J. Patriquin, I. Novitzky-Basso, 2023, Leukemia research.

Influence of conditioning regimen intensity on outcomes post‐allogeneic hematopoietic cell transplantation for acute myeloid leukemia in complete morphological remission

J. Lipton, A. Viswabandya, M. Remberger, 2023, European journal of haematology.

Recurrent focal copy-number changes and loss of heterozygosity implicate two noncoding RNAs and one tumor suppressor gene at chromosome 3q13.31 in osteosarcoma.

A. Shlien, D. Malkin, P. Ray, 2010, Cancer research.

J. Lipton, A. Viswabandya, S. Bhella, 2021, Annals of Hematology.

HCT frailty scale for younger and older adults undergoing allogeneic hematopoietic cell transplantation

J. Lipton, A. Viswabandya, S. Alibhai, 2023, Bone Marrow Transplantation.

Outcomes of ATG-PTCY-CSA vs. ATG-based Prophylaxis for 10/10 HLA Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation: ATG-PTCY-CsA for PB MUD allo-HCT.

A. Viswabandya, E. Atenafu, I. Novitzky-Basso, 2024, Transplantation and cellular therapy.

Dual T cell depletion for graft versus host disease prevention in peripheral blood haploidentical hematopoietic cell transplantation for adults with hematological malignancies.

A. Viswabandya, E. Atenafu, A. Law, 2024, Bone marrow transplantation.

Choosing between older matched sibling donor and younger matched unrelated donor in allogeneic hematopoietic cell transplantation: comparison of clinical outcomes in acute myeloid leukemia and myelodysplastic syndrome.

J. Lipton, A. Viswabandya, M. Remberger, 2023, Transplantation and cellular therapy.